A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 31, 1999

Conditions
HIV Infections
Interventions
DRUG

Enfuvirtide

DRUG

Ritonavir

DRUG

Abacavir sulfate

DRUG

Amprenavir

DRUG

Efavirenz

Trial Locations (20)

10016

New York Univ Med Ctr, New York

15261

Univ of Pittsburgh, Pittsburgh

19106

Pennsylvania Oncology and Hematology Associates, Philadelphia

19107

Philadelphia FIGHT, Philadelphia

21287

Johns Hopkins Hosp, Baltimore

27707

Trimeris Inc, Durham

30308

AIDS Research Consortium of Atlanta, Atlanta

32701

IDC Research Initiative, Altamonte Springs

33316

Gary Richmond MD, Fort Lauderdale

63110

Washington Univ School of Medicine, St Louis

74114

Associates of Med and Mental Health, Tulsa

78705

Central Texas Clinical Research, Austin

90095

UCLA Care Ctr, Los Angeles

90211

Pacific Oaks Research, Beverly Hills

92103

UCSD, San Diego

92262

ViRx Inc, Palm Springs

92270

Donald Northfelt, Palm Springs

94109

ViRx Inc, San Francisco

94115

Quest Clinical Research, San Francisco

200091104

Dupont Circle Physicians Group, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Trimeris

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00002239 - A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults | Biotech Hunter | Biotech Hunter